TY - JOUR
T1 - The Interface of Cancer, Their Microenvironment and Nanotechnology
AU - Roque, Natalia
AU - Matias, Diana
AU - Balça-Silva, Joana
AU - Ferrer, Valéria Pereira
AU - Pessoa, Luciana Santos
AU - de Sampaio e Spohr, Tania Cristina Leite
PY - 2022
Y1 - 2022
N2 - Cancer is one of the deadliest diseases with a cure far from being found. Despite the extraordinary advances in the therapy approaches, only a few patients respond to treatments. The tumor microenvironment (TME) plays a crucial role in cancer progression by contributing to the chemoresistance. Thus, emerging efforts are being made in nanotechnology research focusing on nanoparticles' potential role and their application in immune system modulation. Moreover, the omics have contributed to bioengineering and nanotechnology development by elucidating the mechanisms of cancer and specific biomarkers that could be used as new therapeutic targets. Furthermore, the non-coding microRNA as a target for cancer treatment and creation of organoids for the study of new treatments helped for the new therapeutics' era called personalized medicine. Here we will discuss the role played by TME in tumor initiation and progression we will describe the recent nanotechnology applied to cancer treatment. Specifically, we will describe the potential role of nanoparticles (NPs) and their application in immune system modulation, ultimately leading to circumventing tumor cell proliferation.
AB - Cancer is one of the deadliest diseases with a cure far from being found. Despite the extraordinary advances in the therapy approaches, only a few patients respond to treatments. The tumor microenvironment (TME) plays a crucial role in cancer progression by contributing to the chemoresistance. Thus, emerging efforts are being made in nanotechnology research focusing on nanoparticles' potential role and their application in immune system modulation. Moreover, the omics have contributed to bioengineering and nanotechnology development by elucidating the mechanisms of cancer and specific biomarkers that could be used as new therapeutic targets. Furthermore, the non-coding microRNA as a target for cancer treatment and creation of organoids for the study of new treatments helped for the new therapeutics' era called personalized medicine. Here we will discuss the role played by TME in tumor initiation and progression we will describe the recent nanotechnology applied to cancer treatment. Specifically, we will describe the potential role of nanoparticles (NPs) and their application in immune system modulation, ultimately leading to circumventing tumor cell proliferation.
KW - biomarkers
KW - CAR-T cells and TCR-T cells therapy
KW - immune-checkpoints
KW - microRNAs
KW - nanoparticles
KW - omics
KW - organoids
KW - personalized medicine
KW - Tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85139950838&partnerID=8YFLogxK
U2 - 10.32604/oncologie.2022.024035
DO - 10.32604/oncologie.2022.024035
M3 - Review article
AN - SCOPUS:85139950838
SN - 1292-3818
VL - 24
SP - 371
EP - 411
JO - Oncologie
JF - Oncologie
IS - 3
ER -